Liu 2020.

Methods	Study design: Randomised clinical trial Study duration: January 2018 to April 2019 Duration of follow‐up: 1 month Setting: Hospital
Participants	Number of participants: 72 Inclusion criteria: Diagnosed as HCC; expected survival time > 6 months; Child‐Pugh Class A or B Age (mean ± SD, range ): TACE + MWA: 52.61 ± 10.04 years; TACE alone: 51.49 ± 10.14 years Male (n/total): TACE + MWA: 29/36; TACE alone: 27/36
Interventions	TACE + MWA group (n = 36) Control group (n = 36)
Outcomes	Tumour response: measured by contrast‐enhanced CT at 1 month after treatment Immunological function: measured by blood testing
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.